1. Home
  2. RDW vs RAPP Comparison

RDW vs RAPP Comparison

Compare RDW & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redwire Corporation

RDW

Redwire Corporation

HOLD

Current Price

$5.54

Market Cap

987.6M

Sector

Industrials

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc. Common Stock

HOLD

Current Price

$27.91

Market Cap

1.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDW
RAPP
Founded
2020
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
987.6M
1.2B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
RDW
RAPP
Price
$5.54
$27.91
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$14.50
$46.60
AVG Volume (30 Days)
5.9M
384.6K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$296,147,000.00
N/A
Revenue This Year
$11.89
N/A
Revenue Next Year
$43.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.87
$6.43
52 Week High
$26.66
$42.27

Technical Indicators

Market Signals
Indicator
RDW
RAPP
Relative Strength Index (RSI) 40.46 54.73
Support Level $5.11 $26.92
Resistance Level $5.58 $30.44
Average True Range (ATR) 0.37 1.79
MACD 0.10 0.14
Stochastic Oscillator 54.54 61.58

Price Performance

Historical Comparison
RDW
RAPP

About RDW Redwire Corporation

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: